



Supplemental Figure S9

A



B



**Supp Figure S9.** (A) Re-sensitization of Cetuximab resistant cells by targeting MAPK signalling. Clonogenic survival assays at 21 days in the CCK-81 parental cell line and 3 Cetuximab-resistant clones from the ENU screen (ENU-10, ENU-5 and ENU-18) treated with Cetuximab (0, 1 or 10μg/ml) combined with the BRAF inhibitor Dabrafenib (16nM) or the MEK1 inhibitor Trametinib (1-20nM). The ENU-derived resistance mutation detected in each resistant clone is indicated in brackets. Below each figure is a heatmap of the viability normalised to each control well. (B) Immunoblot of CCK-81 cell line and mutant ENU clones (mutation indicated for each clone) treated with Cetuximab (10μg/ml), Trametinib (10nM) or a combination of both for 3 hours and pERK/total ERK assayed.